<code id='5186C2FC6A'></code><style id='5186C2FC6A'></style>
    • <acronym id='5186C2FC6A'></acronym>
      <center id='5186C2FC6A'><center id='5186C2FC6A'><tfoot id='5186C2FC6A'></tfoot></center><abbr id='5186C2FC6A'><dir id='5186C2FC6A'><tfoot id='5186C2FC6A'></tfoot><noframes id='5186C2FC6A'>

    • <optgroup id='5186C2FC6A'><strike id='5186C2FC6A'><sup id='5186C2FC6A'></sup></strike><code id='5186C2FC6A'></code></optgroup>
        1. <b id='5186C2FC6A'><label id='5186C2FC6A'><select id='5186C2FC6A'><dt id='5186C2FC6A'><span id='5186C2FC6A'></span></dt></select></label></b><u id='5186C2FC6A'></u>
          <i id='5186C2FC6A'><strike id='5186C2FC6A'><tt id='5186C2FC6A'><pre id='5186C2FC6A'></pre></tt></strike></i>

          entertainment

          entertainment

          author:knowledge    Page View:83
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more
          FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted
          FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

          DarronCummings/APScientistsattheFoodandDrugAdministrationhavetwobigquestionsaboutEliLilly’sexperimen

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          FDA panel to weigh approval of NurOwn, controversial ALS drug

          AdobeYearsofpolarizingscientificdiscourseandbruisingonlinedebatewillcometoaheadnextweekwhenadviserst